2BBBullish & Bearish
Phio Pharmaceuticals Corp. (PHIO) trades on NASDAQ. It operates in the Health Care sector, Biotechnology industry. Its current 2BB score is 26 out of 100.
Phio Pharmaceuticals Corporation is a US clinical stage biotechnology company developing its INTASYL siRNA in immuno-oncology. Formerly known as RXi Pharmaceuticals, the company's name was changed to Phio Pharmaceuticals in 2018.
Phio Pharmaceuticals Corp.’s current 2BB score is 26 out of 100, built from the signal categories below.
| Signal | Score | Reading |
|---|---|---|
| Activity | 5 | Very Low |
| Momentum | 34 | Weakening |
| Financial strength | 17 | Very Weak |
| Quality | 20 | Weak |
| Risk | 41 | Moderate |
| Founded | 2011 |
| Employees | 6 |
| 52-week range | $0.81 – $4.19 |
| Report date | EPS actual | EPS estimate | Revenue actual | Revenue estimate |
|---|---|---|---|---|
| 2026-11-11 | — | -0.3315 | — | $0.00 |
| 2026-08-12 | — | -0.3672 | — | $0.00 |
| 2026-05-13 | — | -0.2397 | — | $0.00 |
| 2026-03-05 | -0.253 | -0.3468 | $0.00 | $0.00 |